Status report of lipid-lowering trials in diabetes

Current Opinion in Lipidology

Volumn 11, Issue 6, 2000, Pages 621-626

  Betteridge, D John ^a,c   Colhoun, Helen ^a   Armitage, Jane ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b RADCLIFFE INFIRMARY   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; FENOFIBRATE;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DYSLIPIDEMIA; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION;

ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; ARTERIOSCLEROSIS; CLINICAL TRIALS; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; HEPTANOIC ACIDS; HUMANS; HYPERLIPIDEMIAS; PROCETOFEN; PYRROLES; RISK FACTORS;

EID: 0033663899     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200012000-00009     Document Type: Review

References (35)

1. Diabetes and atherosclerosis: An epidemiological view
2. Epidemiology of macrovascular disease in diabetes
3. Diabetes and atherosclerosis: An epidemiologic view
4. Atherogenesis in diabetes
5. Why is diabetes mellitus a stronger risk factor for fatal ischaemic heart disease in women than in men?
6. Diabetes and decline in heart disease mortality in US adults
7. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction
8. Impact of diabetes on mortality after the first myocardial infarction
9. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: The Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries experience
10. Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction
11. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease
12. Diabetes mellitus, a predictor of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD) trials and registry
13. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus
14. Effects of rampiril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
15. The aspirin papers: Aspirin benefits patients with vascular disease and those undergoing revascarulization
16. α-Blockers and sudden cardiac death
17. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
18. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the Cholesterol and Recurrent Events (CARE) Trial
19. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels. Subgroup analysis of the Scandinavian Simvastatin Survival Study
20. Patients with type 2 diabetes: The case for primary prevention
21. Diabetes and cardiovascular disease. A statement for Healthcare Professionals from the American Heart Association
22. Risk factors for coronary artery disease in non insulin dependent diabetes mellitus (UKPDS 23)
23. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPs/TexCAPs
24. Coronary heart disease in NIDDM patients in the Helsinki Heart Study
25. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia
26. Management of dyslipidaemia in adults with diabetes
27. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
28. Prevention of coronary heart disease in clinical practice. Recommendations of the second joint task force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension
29. The Diabetes Atherosclerosis Intervention Study (DAIS): A study conducted in cooperation with the World Health Organization
30. Baseline characteristics of the study population in the Diabetes Atherosclerosis Intervention Study (DAIS)
31. Diabetes Atherosclerosis Intervention Study (DAIS): Quantitative coronary angiographic analysis of coronary artery atherosclerosis
32. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of anti-oxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease: Early safety and efficacy experience
33. Need for large scale randomised evidence about lowering LDL-cholesterol in people with diabetes mellitus. MRC/BHF Heart Protection Study and other major trials
34. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type II diabetes (UKPDS 33)
35. Diabetes, lipids and coronary heart disease: What have we learnt from lipid lowering trials?